Display options
Share it on

Perm J. 2008;12(1):32-7. doi: 10.7812/tpp/07-091.

Current status and treatment of primary hyperparathyroidism.

The Permanente journal

Dina M Elaraj, Orlo H Clark

PMID: 21369510 PMCID: PMC3042336 DOI: 10.7812/tpp/07-091

Abstract

Primary hyperparathyroidism (HPT) is diagnosed in approximately 100,000 patients in the US each year, with a 2-3:1 female-to-male distribution. In most cases, occurrence is sporadic rather than familial, and 80% to 85% of cases of sporadic primary HPT are caused by a solitary parathyroid adenoma. The diagnosis is made by hypercalcemia with an inappropriately elevated parathyroid hormone (PTH) level and a 24-hour urine calcium excretion level that is normal or high. Truly asymptomatic primary HPT is rare, as most patients have symptoms or metabolic complications when carefully evaluated by standardized health questionnaires. The National Institutes of Health (NIH) published guidelines in 2002, recommending parathyroidectomy for all symptomatic patients and for asymptomatic patients less than age 50 years or those who cannot participate in medical surveillance. These criteria have been called into question as being too limited, because multiple studies have demonstrated symptomatic and metabolic benefits of parathyroidectomy in "asymptomatic" patients. Given the studies showing an improvement in quality-of-life measures, future risk for developing renal calculi, bone density, cardiovascular health, and risk of death, we believe that virtually all patients with primary HPT should undergo surgical resection. An improvement in preoperative localization studies as well as the development of a rapid intraoperative PTH assay has changed the approach to parathyroid surgery since the 1980s. Because most sporadic primary HPT is caused by a single gland adenoma, our preferred procedure has now changed from a bilateral neck exploration to a focused or unilateral approach, with similar rates of success in patients with a solitary tumor identified preoperatively.

References

  1. Arch Surg. 2002 Aug;137(8):896-9; discussion 899-900 - PubMed
  2. J Bone Miner Res. 1991 Oct;6 Suppl 2:S135-42; discussion 151-2 - PubMed
  3. JAMA. 1990 Aug 1;264(5):581-4 - PubMed
  4. Surgery. 1988 Dec;104(6):1121-7 - PubMed
  5. J Urol. 1984 Dec;132(6):1204-7 - PubMed
  6. Lancet. 1973 Aug 11;2(7824):331-2 - PubMed
  7. Med Lab Sci. 1987 Apr;44(2):115-8 - PubMed
  8. Am J Med. 1974 Oct;57(4):642-8 - PubMed
  9. J Clin Endocrinol Metab. 1981 Apr;52(4):736-40 - PubMed
  10. Surgery. 1982 Nov;92(5):814-21 - PubMed
  11. J Clin Endocrinol Metab. 2004 Nov;89(11):5415-22 - PubMed
  12. Surgery. 1987 Dec;102(6):910-3 - PubMed
  13. Surgery. 2004 Oct;136(4):872-80 - PubMed
  14. BMJ. 2000 Sep 9;321(7261):598-602 - PubMed
  15. Ann Surg. 2002 Nov;236(5):543-51 - PubMed
  16. Eur J Clin Invest. 1998 Apr;28(4):271-6 - PubMed
  17. Surgery. 2006 Oct;140(4):655-63; discussion 653-4 - PubMed
  18. N Engl J Med. 1980 Jan 24;302(4):189-93 - PubMed
  19. Arch Surg. 2006 Sep;141(9):885-9; discussion 889-91 - PubMed
  20. Surgery. 1999 Jun;125(6):608-14 - PubMed
  21. Surgery. 2000 Dec;128(6):1013-20;discussion 1020-1 - PubMed
  22. World J Surg. 2003 Feb;27(2):216-22 - PubMed
  23. J Clin Endocrinol Metab. 1992 Aug;75(2):362-6 - PubMed
  24. Clin Endocrinol (Oxf). 1999 Mar;50(3):321-8 - PubMed
  25. Endocr Pract. 2005 Jan-Feb;11(1):49-54 - PubMed
  26. J Bone Miner Res. 1991 Oct;6 Suppl 2:S1-166 - PubMed
  27. Arch Intern Med. 1989 Aug;149(8):1887-90 - PubMed
  28. J Am Coll Surg. 2003 Apr;196(4):535-40 - PubMed
  29. Surgery. 1986 Jun;99(6):643-51 - PubMed
  30. Ann Surg. 2004 Apr;239(4):528-35 - PubMed
  31. Ann Surg. 1995 Sep;222(3):402-12; discussion 412-4 - PubMed
  32. J Bone Miner Res. 2002 Nov;17 Suppl 2:N30-6 - PubMed
  33. J Clin Endocrinol Metab. 2002 Dec;87(12):5353-61 - PubMed
  34. Surgery. 2001 Jun;129(6):720-9 - PubMed
  35. Br J Surg. 1982 May;69(5):244-7 - PubMed
  36. Am J Kidney Dis. 1995 Nov;26(5):801-7 - PubMed

Publication Types